Abstract: A method of treating a sintered mining insert including cemented carbide includes the step of subjecting the mining insert to a surface hardening process. The surface hardening process is executed at an elevated temperature of or above 100° C. A mining insert is also provided, wherein the HV1 Vickers hardness measurement increase (HV1%) from the surface region, measured as an average of HV1 measurements taken at 100 ?m, 200 ?m and 300 ?m below the surface, compared to the HV1 Vickers hardness measured in the bulk (HV1bulk), is at least 8.05-0.00350×HV1bulk.

Abstract: A coated cutting tool has a CVD coating and a substrate of a cemented carbide, wherein the metallic binder in the cemented carbide includes Ni. The CVD coating has an inner layer of TiN and a subsequent layer of TiCN. A C-activity relative to graphite in the metallic binder is lower than 0.15 and an average d electron value of the metallic binder is 7.00-7.43, wherein an interface between the substrate and the inner TiN layer is free of Ti-containing intermetallic phase.

Abstract: A coated cutting tool has a CVD coated and a substrate of a cemented carbide, wherein the metallic binder in the cemented carbide includes Ni. The CVD coating has an inner layer of TiN and a subsequent layer of TiCN. The C-activity relative to graphite in the metallic binder is lower than 0.15 and an average d electron value of the metallic binder is 7.00-7.43, wherein an interface between the substrate and the inner TiN layer is free of Ti-containing intermetallic phase.

Abstract: A method of redistributing the binder phase of a cemented carbide mining insert having a WC hard-phase component, optionally one or more further hard-phase components and a binder includes the steps of providing a green cemented carbide mining insert; applying at least one binder puller selected from a metal oxide or a metal carbonate to only at least one local area of the surface of the green cemented carbide insert; sintering the green carbide mining insert to form a sintered cemented carbide insert; and subjecting the sintered cemented carbide insert to dry tumbling process executed at an elevated temperature of or above 100° C., preferably at a temperature of or above 200° C., more preferably at a temperature of between 200° C. and 450° C.

Abstract: A cutting tool includes a cemented carbide substrate. The cemented carbide consists of hard constituents in a metallic binder. The hard constituents include WC. The WC content in the cemented carbide is 80-93 wt %. The cemented carbide has Ni and Al, and a Ni content of 3-13 wt %, a weight ratio of Co/Ni<0.33, a weight ratio of Fe/Ni<0.25, a weight ratio of Cr/Ni<0.25 and a weight ratio of 0.02<Al/(Ni+Co+Fe)<0.1. The crack resistance W is defined as the ratio of the load applied on a Vickers hardness indentation and the total crack length of the cracks formed at the corners of the Vickers hardness indentation. The product of the hardness H(rake) at the rake face and the crack resistance W(rake) at the rake face is H(rake)*W(rake)>5000 HV100*N/?m.

Abstract: A cutting tool includes a substrate of cemented carbide having hard constituents in a metallic binder. The hard constituents include WC. The WC content in the cemented carbide is 80-95 wt %. The cemented carbide has a Fe+Ni+Co+Cr content of 3-13 wt %, an atomic ratio of 0.05<Fe/(Fe+Ni+Co+Cr)<0.35, an atomic ratio of 0.05<Ni/(Fe+Ni+Co+Cr)<0.35, an atomic ratio of 0.05<Co/(Fe+Ni+Co+Cr)<0.35 and an atomic ratio of 0.05<Cr/(Fe+Ni+Co+Cr)<0.35. The crack resistance W measured on the rake face of the cutting tool is at least 25% higher than the W measured on a cross section of the bulk area of the cutting tool.

Abstract: A method of treating a sintered mining insert including cemented carbide includes the step of subjecting the mining insert to a surface hardening process. The surface hardening process is executed at an elevated temperature of or above 100° C. A mining insert is also provided, wherein the HV1 Vickers hardness measurement increase (HV1%) from the surface region, measured as an average of HV1 measurements taken at 100 ?m, 200 ?m and 300 ?m below the surface, compared to the HV1 Vickers hardness measured in the bulk (HV1bulk), is at least 8.05-0.00350×HV1bulk.

Abstract: A cutting tool includes a substrate of cemented carbide including hard constituents in a metallic binder. The hard constituents includes WC and the WC content in the cemented carbide is 80-96 wt%. The cemented carbide has a Ni content of 2.5-13 wt%, a weight ratio of Fe / Ni < 1.5 and a weight ratio of Co / Ni < 0.825. The cutting tool includes a rake face, a flank face and a cutting edge there between, wherein the hardness H is measured with Vickers indentation and the crack resistance W is the ratio of the load to the total crack lengths of the cracks in the corners of said Vickers indentation. The product of the hardness at the rake face H(rake) and the crack resistance at the rake face W(rake) for the cutting tool is H(rake)*W(rake) > 2000 HV100*N/µm.

Abstract: The present disclosure relates to a method of treating a cutting tool of a cemented carbide or cermet substrate, wherein the cutting tool is subjected to shot peening at a temperature of or above 100° C. The cutting tool typically has a rake face, a flank face and a cutting edge extending therebetween. The shot peening is performed at least on the rake face of the cutting tool. The present disclosure also relates to a cutting tool treated with the method.

Abstract: An implantable medical device applies an electric signal to at least a portion of a heart in a subject. A resulting electric signal is collected from the heart and is used together with the applied signal for determining a cardiogenic impedance signal. The impedance signal is processed in order to estimate an isovolumetric contraction time, an isovolumetric relaxation time and an ejection time for a heart cycle. These three time parameters are employed for calculating a Tei-index of the heart. The Tei-index can be used as myocardial performance parameter in heart diagnosis and/or cardiac therapy adjustment.

Abstract: Methods and systems for optimizing stimulation of a heart of a patient are disclosed. The method comprises: determining recommended pacing settings including recommended AV delays and/or recommended VV delays based on IEGM data. Further, at least one hemodynamical parameter is determined based on measured at least one hemodynamical signal. Reference pacing settings are determined including reference AV delays and/or reference VV delays based on said hemodynamical parameters. An AV delay correction value and a VV delay correction value are calculated as a difference between recommended AV and/or VV delays and reference AV and/or VV delays, respectively. The correction values are used for updating recommended AV and/or VV delays, respectively.

Abstract: An implantable medical device has an impedance processor for determining atrial impedance data reflective of the cardiogenic impedance of an atrium of a heart during diastole and/or systole of heart cycle. Ventricular impedance data reflective of the cardiogenic impedance of a ventricle during diastole and/or systole are also determined. The determined impedance data are processed by a representation processor for estimating a diastolic and/or a systolic atrial impedance representation and a diastolic and/or a systolic ventricular impedance representation. A condition processor determines the presence of any heart valve malfunction, such as valve regurgitation and/or stenosis, of at least one heart valve based on the estimated atrial and ventricular impedance representations.

Abstract: An implantable medical device has an impedance processor for determining atrial impedance data reflective of the cardiogenic impedance of an atrium of a heart during diastole and/or systole of heart cycle. Ventricular impedance data reflective of the cardiogenic impedance of a ventricle during diastole and/or systole are also determined. The determined impedance data are processed by a representation processor for estimating a diastolic and/or a systolic atrial impedance representation and a diastolic and/or a systolic ventricular impedance representation. A condition processor determines the presence of any heart valve malfunction, such as valve regurgitation and/or stenosis, of at least one heart valve based on the estimated atrial and ventricular impedance representations.

Abstract: An implantable medical device applies an electric signal to at least a portion of a heart in a subject. A resulting electric signal is collected from the heart and is used together with the applied signal for determining a cardiogenic impedance signal. The impedance signal is processed in order to estimate an isovolumetric contraction time, an isovolumetric relaxation time and an ejection time for a heart cycle. These three time parameters are employed for calculating a Tei-index of the heart. The Tei-index can be used as myocardial performance parameter in heart diagnosis and/or cardiac therapy adjustment.

Abstract: An implantable medical device has an impedance processor that determines impedance data reflective of the transvalvular impedance of a heart valve of a heart during a heart cycle. The determined impedance data are processed by a representation processor that estimates diastolic and systolic transvalvular impedance representations. A condition processor determines the presence of any heart valve malfunction, such as valve regurgitation and/or stenosis, of the heart valve based on the estimated diastolic and systolic transvalvular impedance representations.

Abstract: An implantable medical device applies an electric signal to at least a portion of a heart in a subject. A resulting electric signal is collected from the heart and is used together with the applied signal for determining a cardiogenic impedance signal. The impedance signal is processed in order to estimate an isovolumetric contraction time, an isovolumetric relaxation time and an ejection time for a heart cycle. These three time parameters are employed for calculating a Tei-index of the heart. The Tei-index can be used as myocardial performance parameter in heart diagnosis and/or cardiac therapy adjustment.

Abstract: An implantable medical device has an impedance processor that determines impedance data reflective of the transvalvular impedance of a heart valve of a heart during a heart cycle. The determined impedance data are processed by a representation processor that estimates diastolic and systolic transvalvular impedance representations. A condition processor determines the presence of any heart valve malfunction, such as valve regurgitation and/or stenosis, of the heart valve based on the estimated diastolic and systolic transvalvular impedance representations.

Abstract: An implantable medical device has an impedance processor for determining atrial impedance data reflective of the cardiogenic impedance of an atrium of a heart during diastole and/or systole of heart cycle. Ventricular impedance data reflective of the cardiogenic impedance of a ventricle during diastole and/or systole are also determined. The determined impedance data are processed by a representation processor for estimating a diastolic and/or a systolic atrial impedance representation and a diastolic and/or a systolic ventricular impedance representation. A condition processor determines the presence of any heart valve malfunction, such as valve regurgitation and/or stenosis, of at least one heart valve based on the estimated atrial and ventricular impedance representations.

Abstract: An implantable medical device has an impedance processor for determining atrial impedance data reflective of the cardiogenic impedance of an atrium of a heart during diastole and/or systole of heart cycle. Ventricular impedance data reflective of the cardiogenic impedance of a ventricle during diastole and/or systole are also determined. The determined impedance data are processed by a representation processor for estimating a diastolic and/or a systolic atrial impedance representation and a diastolic and/or a systolic ventricular impedance representation. A condition processor determines the presence of any heart valve malfunction, such as valve regurgitation and/or stenosis, of at least one heart valve based on the estimated atrial and ventricular impedance representations.

Abstract: An implantable medical device has an impedance processor that determines impedance data reflective of the transvalvular impedance of a heart valve of a heart during a heart cycle. The determined impedance data are processed by a representation processor that estimates diastolic and systolic transvalvular impedance representations. A condition processor determines the presence of any heart valve malfunction, such as valve regurgitation andor stenosis, of the heart valve based on the estimated diastolic and systolic transvalvular impedance representations.